menu
    • menu
    [{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"MycoMedica Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MycoMedica Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MycoMedica Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"MycoMedica Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MycoMedica Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MycoMedica Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Enveric Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Psilocybin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"MycoMedica Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"MycoMedica Life Sciences \/ MycoMedica Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"MycoMedica Life Sciences \/ MycoMedica Life Sciences"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Obvious Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"MycoMedica Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"MycoMedica Life Sciences \/ Obvious Ventures","highestDevelopmentStatusID":"1","companyTruncated":"MycoMedica Life Sciences \/ Obvious Ventures"},{"orgOrder":0,"company":"MycoMedica Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase I","graph3":"MycoMedica Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MycoMedica Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MycoMedica Life Sciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by MycoMedica Life Sciences

    Menu

    MycoMedica Life Sciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MLS101 (Psilocybin) Safety, Tolerability and PK In Healthy Volunteers

                            Details : Psilocybin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Nervous System Diseases.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 03, 2025

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybin Prodrug

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Enveric Biosciences

                            Deal Size : $62.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

                            Details : MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodrug of the active metabolite psilocin, in treatment of neuropsychiatric disorders such as depression.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : Psilocybin Prodrug

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Enveric Biosciences

                            Deal Size : $62.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Part...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 16, 2024

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 22, 2024

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed

                            MycoMedica Life Sciences

                            U.S.A arrow
                            ESCRS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Obvious Ventures

                            Deal Size : $60.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            MycoMedica Life Sciences, PBC Secures $60 Million in Funding To Fuel Fungi-Based Drug Development for Preventi...

                            Details : The proceeds from the financing will be used to advance the company’s next stage of operations having psilocybine on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 06, 2022

                            Lead Product(s) : Psilocybine

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Obvious Ventures

                            Deal Size : $60.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth